Netruna as A Potential Drug Target (G9423)

Target Name: NTN1

NCBI ID: G9423

NTN1

Netruna as A Potential Drug Target

Netruna (NTN1) is a non-coding RNA molecule that has been identified as a potential drug target (1) and a biomarker for various diseases, including cancer (2), neurodegenerative diseases (3), and autoimmune diseases (4).NTN1 is a key regulator of gene expression and has been shown to play a role in the regulation of cell growth, apoptosis, and inflammation.

Expression and function of NTN1

NTN1 is a non-coding RNA molecule that is expressed in a variety of tissues and cells. It is primarily expressed in the brain and testes, but is also found in other tissues, including placenta, liver, and muscle. NTN1 has been shown to play a role in the regulation of gene expression by binding to specific DNA sequences and interacting with proteins such as RNA-protein hybrids.

One of the most well-studied functions of NTN1 is its role in cell apoptosis. NTN1 has been shown to be involved in the regulation of cell apoptosis by binding to the protein Bcl-2 and preventing its binding to the protein Apo-1. Bcl-2 is a protein that has been shown to play a role in the regulation of apoptosis, and NTN1 has been shown to inhibit its binding to Apo-1 by cleaving the Apo-1 protein.

In addition to its role in cell apoptosis, NTN1 has also been shown to be involved in the regulation of cell growth. NTN1 has been shown to play a role in the regulation of cell T-cell proliferation by binding to the protein NF-kappa-B and preventing its binding to the protein p21.

NTN1 as a potential drug target

NTN1 has been identified as a potential drug target due to its involvement in the regulation of cell apoptosis and growth. Drugs that target NTN1 have been shown to have therapeutic effects in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the most well-studied drugs that targets NTN1 is the drugletis. Letis is a small molecule inhibitor of NTN1 that has been shown to inhibit the activity of NTN1 in cell apoptosis and cell growth. Letis has been shown to be effective in treating a variety of diseases, including neurodegenerative diseases (12) and cancer.

Another drug that targets NTN1 is the drug Y27632. Y27632 is a small molecule inhibitor of NTN1 that has been shown to inhibit the activity of NTN1 in cell apoptosis and cell growth. Y27632 has been shown to be effective in treating a variety of diseases, including neurodegenerative diseases (15) and cancer.

Conclusion

NTN1 is a non-coding RNA molecule that has been shown to play a role in the regulation of cell apoptosis and growth. It is expressed in a variety of tissues and cells and has been shown to play a role in the regulation of gene expression by binding to specific DNA sequences and interacting with proteins such as RNA-protein hybrids. NTN1 has also been shown to be involved in the regulation of cell apoptosis and has been identified as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The drugs Letis and Y27632 are currently being studied as potential treatments for these diseases.

Protein Name: Netrin 1

Functions: Netrins control guidance of CNS commissural axons and peripheral motor axons. Its association with either DCC or some UNC5 receptors will lead to axon attraction or repulsion, respectively. Binding to UNC5C might cause dissociation of UNC5C from polymerized TUBB3 in microtubules and thereby lead to increased microtubule dynamics and axon repulsion (PubMed:28483977). Involved in dorsal root ganglion axon projection towards the spinal cord (PubMed:28483977). It also serves as a survival factor via its association with its receptors which prevent the initiation of apoptosis. Involved in tumorigenesis by regulating apoptosis (PubMed:15343335)

The "NTN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NTN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets